A detailed history of State Street Corp transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, State Street Corp holds 80,353 shares of IKNA stock, worth $126,154. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,353
Previous 80,353 -0.0%
Holding current value
$126,154
Previous $132,000 5.3%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.24 - $1.82 $498,842 - $732,171
-402,292 Reduced 83.35%
80,353 $132,000
Q1 2024

May 15, 2024

BUY
$1.27 - $2.0 $91,313 - $143,800
71,900 Added 17.5%
482,645 $685,000
Q4 2023

Feb 14, 2024

BUY
$1.33 - $4.4 $18,221 - $60,280
13,700 Added 3.45%
410,745 $809,000
Q3 2023

Nov 14, 2023

BUY
$4.09 - $6.43 $53,951 - $84,818
13,191 Added 3.44%
397,045 $1.72 Million
Q2 2023

Aug 14, 2023

BUY
$3.5 - $7.31 $1.13 Million - $2.37 Million
323,901 Added 540.26%
383,854 $2.52 Million
Q1 2023

May 15, 2023

BUY
$2.62 - $4.97 $24,104 - $45,724
9,200 Added 18.13%
59,953 $206,000
Q4 2022

Feb 14, 2023

BUY
$2.0 - $3.7 $38,400 - $71,040
19,200 Added 60.85%
50,753 $135,000
Q3 2022

Nov 15, 2022

SELL
$3.46 - $6.0 $43,952 - $76,218
-12,703 Reduced 28.7%
31,553 $112,000
Q2 2022

Aug 15, 2022

SELL
$3.23 - $7.4 $1.16 Million - $2.67 Million
-360,346 Reduced 89.06%
44,256 $196,000
Q1 2022

May 16, 2022

BUY
$5.61 - $13.85 $358,972 - $886,233
63,988 Added 18.79%
404,602 $2.47 Million
Q4 2021

Feb 14, 2022

BUY
$10.52 - $16.96 $2.19 Million - $3.53 Million
208,146 Added 157.13%
340,614 $4.27 Million
Q3 2021

Nov 15, 2021

BUY
$9.82 - $15.23 $550,077 - $853,123
56,016 Added 73.27%
132,468 $1.67 Million
Q2 2021

Aug 16, 2021

BUY
$13.27 - $26.0 $1.01 Million - $1.99 Million
76,452 New
76,452 $1.07 Million

Others Institutions Holding IKNA

About Ikena Oncology, Inc.


  • Ticker IKNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,257,500
  • Market Cap $56.9M
  • Description
  • Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...
More about IKNA
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.